Wednesday, 24 August 2016

Detailed Report on Oxysterols Receptor LXR-BetaLiver X Receptor Beta -Pipeline Review, H1 2016

Oxysterols Receptor LXR-BetaLiver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB-Pipeline Review, H1 2016 ​is a new market research publication announced by Reportstack. This report provides in depth analysis on Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) targeted pipeline therapeutics. 
The report provides comprehensive information on the Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) targeted therapeutics development and features dormant and discontinued projects.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic landscape for Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB)
- The report reviews Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB)
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Companies Mentioned
Affichem SA Bristol-Myers Squibb Company Vitae Pharmaceuticals, Inc.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###

posted by Reportstack @ 02:12   0 Comments

Research delivers insight into the Cathepsin KCathepsin O -Pipeline Review, H1 2016

Cathepsin KCathepsin O or Cathepsin X or EC 3.4.22.38-Pipeline Review, H1 2016 ​is a new market research publication announced by Reportstack. This report provides in depth analysis on Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) targeted pipeline therapeutics.
The report provides comprehensive information on the Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) targeted therapeutics development and features dormant and discontinued projects.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic landscape for Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38)
- The report reviews Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Companies Mentioned
Amura Holdings Limited Medivir AB Merck & Co., Inc. Virobay Inc. Wroclawskie Centrum Badan EIT+ Sp. z o.o.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###

posted by Reportstack @ 02:02   0 Comments

Market Research on 2 kDa Type IV CollagenaseMatrix Metalloproteinase 2 -Pipeline Review, H1 2016

72 kDa Type IV CollagenaseMatrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or MMP2 or EC 3.4.24.24-Pipeline Review, H1 2016 ​is a new market research publication announced by Reportstack. This report provides in depth analysis on 72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or MMP2 or EC 3.4.24.24) targeted pipeline therapeutics.
The report provides comprehensive information on the 72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or MMP2 or EC 3.4.24.24), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in 72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or MMP2 or EC 3.4.24.24) targeted therapeutics development and features dormant and discontinued projects.
To view the table of contents and know more details please visit 72 kDa Type IV CollagenaseMatrix Metalloproteinase 2 -Pipeline Review, H1 2016
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic landscape for 72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or MMP2 or EC 3.4.24.24)
- The report reviews 72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or MMP2 or EC 3.4.24.24) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report reviews latest news and deals related to 72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or MMP2 or EC 3.4.24.24) targeted therapeutics
Reasons to buy
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding 72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or MMP2 or EC 3.4.24.24) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###

posted by Reportstack @ 01:59   0 Comments

New Report Explores on Interleukin 15IL15-Pipeline Review, H1 2016

Interleukin 15IL15-Pipeline Review, H1 2016 is a new market research publication announced by Reportstack. This report provides in depth analysis on Interleukin 15 (IL15) targeted pipeline therapeutics.
The report provides comprehensive information on the Interleukin 15 (IL15), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 15 (IL15) targeted therapeutics development and features dormant and discontinued projects.
To access full report with TOC, please visit Interleukin 15IL15-Pipeline Review, H1 2016
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic landscape for Interleukin 15 (IL15)
- The report reviews Interleukin 15 (IL15) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Interleukin 15 (IL15) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Interleukin 15 (IL15)
- Devise corrective measures for pipeline projects by understanding Interleukin 15 (IL15) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Companies Mentioned
Amgen Inc. Calypso Biotech SA Digna Biotech, S.L.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###

posted by Reportstack @ 01:56   0 Comments

Tuesday, 23 August 2016

Market Research Outlook on Intercellular Adhesion Molecule 1ICAM-1 -Pipeline Review, H1 2016

Intercellular Adhesion Molecule 1ICAM-1 or Major Group Rhinovirus Receptor or CD54-Pipeline Review, H1 2016 ​is a new market research publication announced by Reportstack. This report provides in depth analysis on Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) targeted pipeline therapeutics.
The report provides comprehensive information on the Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) targeted therapeutics development and features dormant and discontinued projects.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic landscape for Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) 
- The report reviews Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report reviews latest news and deals related to Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Companies Mentioned
Atlantic Healthcare Plc China Medical System Holdings Limited DiNonA Inc. MingSight Pharmaceuticals RXi Pharmaceuticals Corporation
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###

posted by Reportstack @ 23:27   0 Comments

Detailed Research on Nonstructural Protein 4BNS4B-Pipeline Review, H1 2016

Nonstructural Protein 4BNS4B-Pipeline Review, H1 2016 ​is a new market research publication announced by Reportstack. This report provides in depth analysis on Nonstructural Protein 4B (NS4B) targeted pipeline therapeutics.
The report provides comprehensive information on the Nonstructural Protein 4B (NS4B), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Nonstructural Protein 4B (NS4B) targeted therapeutics development and features dormant and discontinued projects.
To access full report with TOC, please visit Nonstructural Protein 4BNS4B-Pipeline Review, H1 2016
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic landscape for Nonstructural Protein 4B (NS4B)
- The report reviews Nonstructural Protein 4B (NS4B) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Nonstructural Protein 4B (NS4B) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Nonstructural Protein 4B (NS4B) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Companies Mentioned
Gilead Sciences, Inc. GlaxoSmithKline Plc Inovio Pharmaceuticals, Inc. Johnson & Johnson Merck & Co., Inc.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###

posted by Reportstack @ 23:25   0 Comments

Market Review on Integrin Beta 7Gut Homing Receptor Beta Subunit -Pipeline Review, H1 2016

Integrin Beta 7Gut Homing Receptor Beta Subunit or ITGB7-Pipeline Review, H1 2016 ​is a new market research publication announced by Reportstack. This report provides in depth analysis on Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted pipeline therapeutics.
The report provides comprehensive information on the Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics development and features dormant and discontinued projects.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The report reviews key players involved in Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics
Reasons to buy
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Companies Mentioned
Genentech, Inc. Protagonist Therapeutics Inc. Takeda Pharmaceutical Company Limited
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###

posted by Reportstack @ 23:22   0 Comments

Recent Report on Potassium Voltage Gated Channel Subfamily A Member 5Voltage Gated Potassium Channel Subunit Kv1.5-Pipeline Review, H1 2016

Potassium Voltage Gated Channel Subfamily A Member 5Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5-Pipeline Review, H1 2016 is a new market research publication announced by Reportstack. This report provides in depth analysis on Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) targeted pipeline therapeutics.
The report provides comprehensive information on the Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) targeted therapeutics development and features dormant and discontinued projects.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic landscape for Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5)
- The report assesses Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Devise corrective measures for pipeline projects by understanding Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Companies Mentioned
AstraZeneca Plc Bristol-Myers Squibb Company Laboratoires Pierre Fabre SA Xention Limited
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###

posted by Reportstack @ 23:15   0 Comments